NeuBase Therapeutics, Inc. (NBSE): Price and Financial Metrics


NeuBase Therapeutics, Inc. (NBSE): $1.02

0.06 (+6.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NBSE Stock Price Chart Interactive Chart >

Price chart for NBSE

NBSE Price/Volume Stats

Current price $1.02 52-week high $5.51
Prev. close $0.96 52-week low $0.89
Day low $0.98 Volume 129,000
Day high $1.04 Avg. volume 114,687
50-day MA $1.42 Dividend yield N/A
200-day MA $2.51 Market Cap 32.90M

NeuBase Therapeutics, Inc. (NBSE) Company Bio


NeuBase Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers drugs for the treatment of dominant genetic disorders and oncogenic mutations causing cancers. NeuBase Therapeutics serves patients in the United States.


NBSE Latest News Stream


Event/Time News Detail
Loading, please wait...

NBSE Latest Social Stream


Loading social stream, please wait...

View Full NBSE Social Stream

Latest NBSE News From Around the Web

Below are the latest news stories about NeuBase Therapeutics Inc that investors may wish to consider to help them evaluate NBSE as an investment opportunity.

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to submit an IND application to the U.S. Food and Drug Administration (FDA) in the fourth quarter (Q4) of calendar year (CY) 2022Good Manufacturing Practice (GMP) manufacturing to support Phase 1/2 clinical trials for

Yahoo | February 11, 2022

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 1, 2022

NeuBase Therapeutics hires new chief financial officer

NeuBase Therapeutics, a Pittsburgh-based developer of genetic medicines, announced that it has hired Todd Branning as its new chief financial officer.

Yahoo | January 11, 2022

NeuBase Therapeutics names Phathom''s Todd Branning as new CFO

NeuBase Therapeutics (NBSE) appoints Todd P. Branning as the company''s new chief financial officer. Prior to joining NeuBase, Branning served as CFO of Phathom Pharmaceuticals (PHAT)…

Seeking Alpha | January 10, 2022

NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and

Yahoo | January 10, 2022

Read More 'NBSE' Stories Here

NBSE Price Returns

1-mo -14.29%
3-mo -28.17%
6-mo -67.20%
1-year -80.27%
3-year -66.34%
5-year -91.77%
YTD -63.70%
2021 -59.80%
2020 -2.92%
2019 300.00%
2018 -95.16%
2017 24.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.625 seconds.